Sunday, June 2, 2013

Characterisation of an Unusual TSE in a Goat by Transmission in Knock-in Transgenic Mice

Characterisation of an Unusual TSE in a Goat by Transmission in Knock-in Transgenic Mice


Rona Wilson, Declan King, Nora Hunter, Wilfred Goldmann and Rona M. Barron1 + Author Affiliations


Neurobiology Division, The Roslin Institute and R(D)SVS, University of Edinburgh, Roslin, Midlothian ↵1 E-mail: rona.barron@roslin.ed.ac.uk Received 18 January 2013. Accepted 24 May 2013.



Abstract



Bovine spongiform encephalopathy (BSE) is a fatal neurodegenerative disorder of cattle, and its transmission to humans through contaminated food is thought to be the cause of the variant form of Creutzfeldt-Jakob disease (vCJD). BSE is believed to have spread from the recycling in cattle of ruminant tissue in meat and bone meal (MBM), however during this time sheep and goats were also exposed to BSE-contaminated MBM. Both sheep and goats are experimentally susceptible to BSE, and while there have been no reported natural BSE cases in sheep, two goat BSE field cases have been documented. While cases of BSE are rare in small ruminants, the existence of scrapie in both sheep and goats is well established. In the UK, during 2006-2007, a serious outbreak of clinical scrapie was detected in a large dairy goat herd. Subsequently, 200 goats were selected for post-mortem examinations, one of which showed biochemical and immunohistochemical features of the disease associated prion protein (PrPTSE) which differed from all other infected goats. In the present study we investigated this unusual case by performing bioassays into a panel of mouse lines. Following characterisation, we found that strain properties such as the ability to transmit to different mouse lines, lesion profile pattern, degree of PrP deposition in the brain and biochemical features of this unusual goat case were neither consistent with goat BSE nor with a goat scrapie herdmate control. However our results suggest this unusual case has BSE-like properties and highlights the need for continued surveillance.












Published Date: 2012-01-04 17:44:07 Subject: PRO/AH/EDR> Prion Disease update 2012 (01) Archive Number: 20120104.0027




PRION DISEASE UPDATE 2012 (01) ******************************





[2] UK: caprine BSE



Date: Sat 3 Dec 2011



Source: Emerging Infectious Diseases 17(12) 12 [edited] http://wwwnc.cdc.gov/eid/article/17/12/11-0333_article.htm Isolation of prion with BSE properties from farmed goat



-------------------------------------------------------



[Authors: Spiropoulos J, Lockey R, Sallis RE, Terry LA, Thorne L, Holder TM, et al. Animal Health and Veterinary Laboratories Agency, Weybridge, Surrey, UK]



Abstract



--------



Transmissible spongiform encephalopathies are fatal neurodegenerative diseases that include variant Creutzfeldt-Jakob disease in humans, scrapie in small ruminants, and bovine spongiform encephalopathy (BSE) in cattle. Scrapie is not considered a public health risk, but BSE has been linked to variant Creutzfeldt-Jakob disease. Small ruminants are susceptible to BSE, and in 2005 BSE was identified in a farmed goat in France. We confirm another BSE case in a goat in which scrapie was originally diagnosed and retrospectively identified as suspected BSE. The prion strain in this case was further characterized by mouse bioassay after extraction from formaldehyde-fixed brain tissue embedded in paraffin blocks. Our data show that BSE can infect small ruminants under natural conditions and could be misdiagnosed as scrapie. Surveillance should continue so that another outbreak of this zoonotic transmissible spongiform encephalopathy can be prevented and public health safeguarded.


Transmissible spongiform encephalopathies (TSEs) are fatal diseases characterized by neurodegenerative changes in the central nervous system that include vacuolation, gliosis, and accumulation of an abnormal isoform (PrPSc) of a naturally occurring host-encoded protein (PrPC) (1). According to the prion hypothesis, PrPSc is the major or the sole infectious agent (1). Although this hypothesis has not received universal acceptance, PrPScis ubiquitous in all known naturally occurring TSEs, and its detection is widely used for their diagnosis.


Bovine spongiform encephalopathy (BSE), a TSE of cattle, was first detected in 1986 (2) and has since been linked with emerging TSEs in other species (3,4) including humans (5,6). Because of its ability to cross species barriers and particularly its zoonotic potential, BSE is considered a public health risk, and extensive measures have been established to detect and eliminate the disease.


Scrapie, a naturally occurring TSE affecting small ruminants, has been known for centuries (7) and is not considered to pose a public health risk (8). Under experimental conditions, however, small ruminants are susceptible to BSE, with pathogenesis and clinical signs that are not readily distinguishable from scrapie (9-12). Additionally, the fact that small ruminants were exposed to BSE-contaminated food before the exclusion of meat and bone meal from ruminant feedstuffs led to the possibility that sheep and goats on commercial farms could be affected by BSE that could be misdiagnosed as scrapie (13,14). The response to this potential risk was the implementation of extensive statutory active surveillance, elimination, and breeding for resistance programs in the European Union (EU).


In 2005, as part of a review of historical TSE-positive cases of sheep and goats in France, a specimen from a goat slaughtered for human consumption in 2002 was reported to be "indistinguishable from a BSE isolate on the basis of all identification criteria available." (15). In response to this report, 2 retrospective studies were initiated in the United Kingdom to analyze archived samples from goat cases that were initially diagnosed as scrapie (16,17). Because only fixed material was available, both studies had to use differential immunohistochemical analysis (D-IHC), a technique that can discriminate scrapie from experimentally induced BSE in sheep (18). These studies identified a single case, originally diagnosed in 1990 as scrapie, that had a D-IHC signature indistinguishable from BSE (16).


Given the wide phenotypic variance of scrapie in sheep and our limited knowledge of this variance in goats, the D-IHC result on its own was insufficient for an unequivocal diagnosis. In accordance with EU regulation 36/2005 (19), the case was referred to the EU Reference Laboratory Strain Typing Expert Group, which recommended further investigation by bioassay.


Bioassay is conventionally undertaken by using unfixed tissues to prepare inocula. Much historical tissue is available only as formalin fixed or formalin fixed and paraffin wax embedded. TSE infectivity persists in such material but with a lower infectious titer than with unfixed frozen tissue (20). However, the potential effects on biological activity, and therefore strain characterization, of fixation and processing are unknown. Thus, further investigation of this case required an extensive panel of controls. We report the results of the bioassay analysis and confirm the diagnosis of BSE in a goat in the United Kingdom.



-- Communicated by: Terry S Singeltary Sr flounder9@verizon.net



[Interested readers should access the original text via the source URL above to view the full text an the references cited. The following has been extracted from the Discussion.


"The 2 cases of naturally occurring BSE in small ruminants, the one reported here and the one identified in France (15), occurred in different countries, during different time periods, and before strict BSE control measures were fully implemented. Therefore, the most likely origin of these 2 cases would be exposure to BSE-contaminated food supplements. Although in France goats constitute 14.3 percent of the small ruminant population, in the United Kingdom they account for only 0.3 percent of small ruminants. It is intriguing, therefore, that the only naturally occurring BSE cases in small ruminants in France and particularly in the United Kingdom were detected in goats and not in sheep, although they have also been exposed to contaminated food supplements. A possible explanation could be that goats are generally managed more intensively than sheep and thus might have been exposed to higher doses of the infectious agent because of the more frequent use of concentrates in intensive dairy farming. Similar observations have been reported in cattle, in which the incidence of BSE was significantly higher in dairy herds and in which management is much more intensive than in beef herds (34). In the United Kingdom, most of the commercial goat herds are kept for milk production in a typically intensive production system, similar to dairy cattle.


The BSE case we have confirmed was 1 of 26 historic goat samples examined in the United Kingdom collected during 1984-2002 (16,17). Since 1993, scrapie in goats has been a notifiable disease in the United Kingdom, and since 2005, samples from all suspected cases of TSE in small ruminants are required to be tested for BSE-like features by using Western blotting (WB) (19). No BSE cases have been identified, although an intermediate case in a goat was reported and is under investigation by bioassay for final resolution (35,36). This screening of brain samples from all small ruminant cases offers reassurance that BSE is not present in the contemporary small ruminant population. However, application of WB to sheep experimentally co-infected with BSE and scrapie detected only the scrapie agent (37). Also, in contrast to BSE, where infectivity is mainly confined to the nervous system, in small ruminants the BSE agent is widely distributed in peripheral tissues and can be transmitted horizontally (11,38). Therefore, feed ban measures alone would be inadequate to control a BSE outbreak in small ruminants. Also, it would be impossible to prevent BSE from entering the human food chain through consumption of food products derived from small ruminants.


Because TSEs in goats are still a problem, particularly in Mediterranean countries, our data suggest that extensive surveillance and breeding schemes must remain in place to prevent a BSE outbreak in small ruminants and to safeguard public health. This report also highlights several issues regarding the use of mouse bioassay to identify TSE strains. As governing bodies seek confirmation of equivocal cases that are identified worldwide, they must be aware of the limitations, cost, and timescale demands of confirming such cases." - Mod.CP]


[See http://healthmap.org/r/1lNY for the interactive HealthMap/ProMED map of the United Kingdom. - Mod.MPP]




******


snip...


******


[5]


Switzerland: BSE Date: Fri 16 Dec 2011 Source: Prionics AG, e-scope newsletter [edited] http://escope.prionics.com/issue/2011-december-4/


In spring 2011, 2 new cases of BSE were discovered in Switzerland [see ProMED-mail posting Prion disease update 2011 (10) 20111107.3317]. Both cases were detected using the Prionics(R)-Check BSE tests. A report has now been published showing that these cases represent a novel type of BSE. What are the consequences of these new BSE cases?


After a period of 4 years without BSE positive cows, in spring this year [2011] Switzerland was shaken by the discovery of 2 new BSE cases detected only one month apart from each other. The cases appeared in different areas of Switzerland and involved animals aged 8 and 15 years, which were tested with the Prionics(R)-Check BSE tests as part of the active disease surveillance program. Bettina Bernhard, Head of the Prionics diagnostic laboratory reported that: "It was the 1st time in 4.5 years that we had found a BSE positive sample in our laboratory. Based on the results from the Prionics(R)-Check WESTERN, we immediately saw that the fingerprint of the prion protein was not that of the classical BSE cases we have detected before. We then informed the Swiss National Reference Laboratory and veterinary authorities and the positive result was confirmed with the Prionics(R)-Check PrioSTRIP."


Novel type of BSE?


------------------


BSE cases that differ from the classical BSE strain have been detected before, however, with low incidence. These atypical strains, designated BASE/L-BSE and H-BSE, were first reported in 2004 in Italy and France. Both strains were detected as part of routine surveillance using the Prionics(R)-Check WESTERN and ELISA tests. The recent publication by Torsten Seuberlich of the Swiss National and OIE [World Organisation for Animal Health] Reference Laboratories for BSE and Scrapie and his colleagues, is showing that these 2 Swiss cases not only differ from classical BSE, but also from the atypical BSE cases found in other countries. It appears that the 2 BSE cases detected in Switzerland seem to represent a novel type of atypical BSE. Dr Seuberlich explains: "We are now undertaking further investigations into these 2 cases and until there is more clarity, surveillance should continue to be carried out at a high level and disease awareness should be increased. Furthermore, we have to ensure that diagnostic techniques are applied that identify such cases."


Continued vigilance needed


--------------------------


Whereas consumption of meat from cows affected by classical BSE has been associated with vCJD, the public health hazard from atypical BSE is unclear. Little is known about its origin and whether it can be transmitted to other animals. These cases show, however, that BSE has not been completely eradicated and that the disease can continue to occur even with current preventive measures (such as the meat-and-bone meal ban) in place. The appearance of new strains of the prion protein could also indicate that BSE is still evolving. Continuous monitoring will be needed to keep these new strains under surveillance.


-- Communicated by: Terry S Singeltary Sr flounder9@verizon.net


[[See http://healthmap.org/r/1AFv for the interactive HealthMap/ProMED map of Switzerland. - Mod.MPP]









Wednesday, January 18, 2012


BSE IN GOATS CAN BE MISTAKEN FOR SCRAPIE February 1, 2012








Saturday, December 3, 2011


Isolation of Prion with BSE Properties from Farmed Goat Volume 17, Number


12—December 2011








Sunday, October 3, 2010


Scrapie, Nor-98 atypical Scrapie, and BSE in sheep and goats North America, who's looking ?








Tuesday, February 01, 2011


Sparse PrP-Sc accumulation in the placentas of goats with naturally acquired scrapie


Research article








Thursday, June 2, 2011


USDA scrapie report for April 2011 NEW ATYPICAL NOR-98 SCRAPIE CASES Pennsylvania AND California








UPDATE PLEASE NOTE ;




AS of June 30, 2011,


snip...


INCLUDING 10 POSITIVE GOATS FROM THE SAME HERD (FIGURE 7).


snip...


see updated APHIS scrapie report ;








Tuesday, February 01, 2011


Sparse PrP-Sc accumulation in the placentas of goats with naturally acquired scrapie


Research article


snip...


Date: Tuesday, February 01, 2011 5:03 PM


To: Mr Terry Singeltary


Subject: Your comment on BMC Veterinary Research 2011, 7:7


Dear Mr Singeltary


Thank you for contributing to the discussion of BMC Veterinary Research 2011, 7:7 .


Your comment will be posted within 2 working days, as long as it contributes to the topic under discussion and does not breach patients' confidentiality or libel anyone. You will receive a further notification by email when the posting appears on the site or if it is rejected by the moderator.


Your posting will read:


Mr Terry Singeltary,


retired


Scrapie cases Goats from same herd USA Michigan


Comment: " In spite of the poorly defined effects of PRNP genetics, scrapie strain, dose, route and source of infection, the caprine placenta may represent a source of infection to progeny and herd mates as well as a source of persistent environmental contamination. "


Could this route of infection be the cause of the many cases of Goat scrapie from the same herd in Michigan USA ?


Has this been investigated ?


(Figure 6) including five goat cases in FY 2008 that originated from the same herd in Michigan. This is highly unusual for goats, and I strenuously urge that there should be an independent investigation into finding the common denominator for these 5 goats in the same herd in Michigan with Scrapie. ...


Kind Regards, Terry






Thursday, January 07, 2010


Scrapie and Nor-98 Scrapie November 2009 Monthly Report Fiscal Year 2010 and FISCAL YEAR 2008








In FY 2010, 72 cases of classical Scrapie and 5 cases of Nor-98 like Scrapie were confirmed...








Scrapie Nor-98 like case in California FY 2011 AS of December 31, 2010.


Scrapie cases in goats FY 2002 - 2011 AS of December 31, 2010 Total goat cases = 21 Scrapie cases, 0 Nor-98 like Scrapie cases (21 field cases, 0 RSSS cases)


Last herd with infected goats disignated in FY 2008 Michigan 8 cases








Tuesday, February 01, 2011


Sparse PrP-Sc accumulation in the placentas of goats with naturally acquired scrapie


Research article











"In spite of the poorly defined effects of PRNP genetics, scrapie strain, dose, route and source of infection, the caprine placenta may represent a source of infection to progeny and herd mates as well as a source of persistent environmental contamination."


Could this route of infection be the cause of the many cases of Goat scrapie from the same herd in Michigan USA ?


Has this been investigated ?


(Figure 6) including five goat cases in FY 2008 that originated from the same herd in Michigan. This is highly unusual for goats, and I strenuously urge that there should be an independent investigation into finding the common denominator for these 5 goats in the same herd in Michigan with Scrapie. ...


Kind Regards, Terry




SNIP...




Scrapie Nor-98 like case in California FY 2011 AS of December 31, 2010.


Scrapie cases in goats FY 2002 - 2011 AS of December 31, 2010 Total goat cases = 21 Scrapie cases, 0 Nor-98 like Scrapie cases (21 field cases, 0 RSSS cases)


Last herd with infected goats disignated in FY 2008 Michigan 8 cases









UPDATED RESPONSE ON MY CONCERNS OF GOAT SCRAPIE IN MICHIGAN ;






----- Original Message -----



From: "BioMed Central Comments"


To:


Sent: Wednesday, February 16, 2011 4:13 AM


Subject: Your comment on BMC Veterinary Research 2011, 7:7


Your discussion posting "Scrapie cases Goats from same herd USA Michigan" has been rejected by the moderator as not being appropriate for inclusion on the site.


Dear Mr Singeltary,


Thank you for submitting your comment on BMC Veterinary Research article (2011, 7:7). We have read your comment with interest but we feel that only the authors of the article can answer your question about further investigation of the route of infection of the five goats in Michigan. We advise that you contact the authors directly rather than post a comment on the article.


With best wishes,


Maria


Maria Kowalczuk, PhD Deputy Biology Editor BMC-series Journals


BioMed Central 236 Gray's Inn Road London, WC1X 8HB


+44 20 3192 2000 (tel) +44 20 3192 2010 (fax)


W: www.biomedcentral.com E: Maria.Kowalczuk@biomedcentral.com


Any queries about this decision should be sent to comments@biomedcentral.com


Regards


BMC Veterinary Research


SNIP...PLEASE SEE FULL TEXT ;




Tuesday, February 01, 2011


Sparse PrP-Sc accumulation in the placentas of goats with naturally acquired scrapie


Research article








Scrapie Nor-98 like case in California FY 2011 AS of December 31, 2010.


Scrapie cases in goats FY 2002 - 2011 AS of December 31, 2010 Total goat cases = 21 Scrapie cases, 0 Nor-98 like Scrapie cases (21 field cases, 0 RSSS cases)


Last herd with infected goats disignated in FY 2008 Michigan 8 cases







Thursday, November 18, 2010


Increased susceptibility of human-PrP transgenic mice to bovine spongiform encephalopathy following passage in sheep








Monday, March 21, 2011


Sheep and Goat BSE Propagate More Efficiently than Cattle BSE in Human PrP Transgenic Mice









*** Most recent positive goat confirmed in April 2013.





Scrapie Cases in Goats FY 2002 – FY 2013 As of April 30, 2013




***SCRAPIE GOATS CALIFORNIA 13 CASES TO DATE ! ***




(an unusually high amount of scrapie documented in goats for a happenstance of bad luck, or spontaneous event, THAT DOES NOT HAPPEN IN OTHER STATES ??? )










Thursday, November 18, 2010


Increased susceptibility of human-PrP transgenic mice to bovine spongiform encephalopathy following passage in sheep







Monday, November 30, 2009


USDA AND OIE COLLABORATE TO EXCLUDE ATYPICAL SCRAPIE NOR-98 ANIMAL HEALTH CODE








Thursday, December 20, 2012


OIE GROUP RECOMMENDS THAT SCRAPE PRION DISEASE BE DELISTED AND SAME OLD BSe WITH BOVINE MAD COW DISEASE








*** The discovery of previously unrecognized prion diseases in both humans and animals (i.e., Nor98 in small ruminants) demonstrates that the range of prion diseases might be wider than expected and raises crucial questions about the epidemiology and strain properties of these new forms. We are investigating this latter issue by molecular and biological comparison of VPSPr, GSS and Nor98.






Tuesday, April 30, 2013


Transmission of classical scrapie via goat milk


Veterinary Record2013;172:455 doi:10.1136/vr.f2613








ALSO, SEE CALIFORNIA AND MICHIGAN FOR THE HIGH SCRAPIE RATE IN GOATS ???


THIS needs to be addressed immediately, as to find the source, route, cause, from this unusual event...tss








Wednesday, November 28, 2012


Scientific and technical assistance on the provisional results of the study on genetic resistance to Classical scrapie in goats in Cyprus 1


SCIENTIFIC REPORT OF EFSA









Thursday, March 29, 2012


atypical Nor-98 Scrapie has spread from coast to coast in the USA 2012


NIAA Annual Conference April 11-14, 2011San Antonio, Texas









*** The discovery of previously unrecognized prion diseases in both humans and animals (i.e., Nor98 in small ruminants) demonstrates that the range of prion diseases might be wider than expected and raises crucial questions about the epidemiology and strain properties of these new forms. We are investigating this latter issue by molecular and biological comparison of VPSPr, GSS and Nor98.


OR-10: Variably protease-sensitive prionopathy is transmissible in bank voles


Romolo Nonno,1 Michele Di Bari,1 Laura Pirisinu,1 Claudia D’Agostino,1 Stefano Marcon,1 Geraldina Riccardi,1 Gabriele Vaccari,1 Piero Parchi,2 Wenquan Zou,3 Pierluigi Gambetti,3 Umberto Agrimi1 1Istituto Superiore di Sanità; Rome, Italy; 2Dipartimento di Scienze Neurologiche, Università di Bologna; Bologna, Italy; 3Case Western Reserve University; Cleveland, OH USA


Background. Variably protease-sensitive prionopathy (VPSPr) is a recently described “sporadic”neurodegenerative disease involving prion protein aggregation, which has clinical similarities with non-Alzheimer dementias, such as fronto-temporal dementia. Currently, 30 cases of VPSPr have been reported in Europe and USA, of which 19 cases were homozygous for valine at codon 129 of the prion protein (VV), 8 were MV and 3 were MM. A distinctive feature of VPSPr is the electrophoretic pattern of PrPSc after digestion with proteinase K (PK). After PK-treatment, PrP from VPSPr forms a ladder-like electrophoretic pattern similar to that described in GSS cases. The clinical and pathological features of VPSPr raised the question of the correct classification of VPSPr among prion diseases or other forms of neurodegenerative disorders. Here we report preliminary data on the transmissibility and pathological features of VPSPr cases in bank voles.


Materials and Methods. Seven VPSPr cases were inoculated in two genetic lines of bank voles, carrying either methionine or isoleucine at codon 109 of the prion protein (named BvM109 and BvI109, respectively). Among the VPSPr cases selected, 2 were VV at PrP codon 129, 3 were MV and 2 were MM. Clinical diagnosis in voles was confirmed by brain pathological assessment and western blot for PK-resistant PrPSc (PrPres) with mAbs SAF32, SAF84, 12B2 and 9A2.


Results. To date, 2 VPSPr cases (1 MV and 1 MM) gave positive transmission in BvM109. Overall, 3 voles were positive with survival time between 290 and 588 d post inoculation (d.p.i.). All positive voles accumulated PrPres in the form of the typical PrP27–30, which was indistinguishable to that previously observed in BvM109 inoculated with sCJDMM1 cases.


In BvI109, 3 VPSPr cases (2 VV and 1 MM) showed positive transmission until now. Overall, 5 voles were positive with survival time between 281 and 596 d.p.i.. In contrast to what observed in BvM109, all BvI109 showed a GSS-like PrPSc electrophoretic pattern, characterized by low molecular weight PrPres. These PrPres fragments were positive with mAb 9A2 and 12B2, while being negative with SAF32 and SAF84, suggesting that they are cleaved at both the C-terminus and the N-terminus. Second passages are in progress from these first successful transmissions.


Conclusions. Preliminary results from transmission studies in bank voles strongly support the notion that VPSPr is a transmissible prion disease. Interestingly, VPSPr undergoes divergent evolution in the two genetic lines of voles, with sCJD-like features in BvM109 and GSS-like properties in BvI109.


The discovery of previously unrecognized prion diseases in both humans and animals (i.e., Nor98 in small ruminants) demonstrates that the range of prion diseases might be wider than expected and raises crucial questions about the epidemiology and strain properties of these new forms. We are investigating this latter issue by molecular and biological comparison of VPSPr, GSS and Nor98.








Wednesday, March 28, 2012


VARIABLY PROTEASE-SENSITVE PRIONOPATHY IS TRANSMISSIBLE, price of prion poker goes up again $








*** The discovery of previously unrecognized prion diseases in both humans and animals (i.e., Nor98 in small ruminants) demonstrates that the range of prion diseases might be wider than expected and raises crucial questions about the epidemiology and strain properties of these new forms. We are investigating this latter issue by molecular and biological comparison of VPSPr, GSS and Nor98.


Increased Atypical Scrapie Detections


Press reports indicate that increased surveillance is catching what otherwise would have been unreported findings of atypical scrapie in sheep. In 2009, five new cases have been reported in Quebec, Ontario, Alberta, and Saskatchewan. With the exception of Quebec, all cases have been diagnosed as being the atypical form found in older animals. Canada encourages producers to join its voluntary surveillance program in order to gain scrapie-free status. The World Animal Health will not classify Canada as scrapie-free until no new cases are reported for seven years. The Canadian Sheep Federation is calling on the government to fund a wider surveillance program in order to establish the level of prevalence prior to setting an eradication date. Besides long-term testing, industry is calling for a compensation program for farmers who report unusual deaths in their flocks.








Thursday, March 29, 2012


atypical Nor-98 Scrapie has spread from coast to coast in the USA 2012


NIAA Annual Conference April 11-14, 2011San Antonio, Texas








Monday, April 25, 2011


Experimental Oral Transmission of Atypical Scrapie to Sheep


Volume 17, Number 5-May 2011 However, work with transgenic mice has demonstrated the potential susceptibility of pigs, with the disturbing finding that the biochemical properties of the resulting PrPSc have changed on transmission (40).








***The pathology features of Nor98 in the cerebellum of the affected sheep showed similarities with those of sporadic Creutzfeldt-Jakob disease in humans.








*** Intriguingly, these conclusions suggest that some pathological features of Nor98 are reminiscent of Gerstmann-Sträussler-Scheinker disease.


119








*** These observations support the view that a truly infectious TSE agent, unrecognized until recently, infects sheep and goat flocks and may have important implications in terms of scrapie control and public health.








Surprisingly the TSE agent characteristics were dramatically different v/hen passaged into Tg bovine mice. The recovered TSE agent had biological and biochemical characteristics similar to those of atypical BSE L in the same mouse model. Moreover, whereas no other TSE agent than BSE were shown to transmit into Tg porcine mice, atypical scrapie was able to develop into this model, albeit with low attack rate on first passage.


Furthermore, after adaptation in the porcine mouse model this prion showed similar biological and biochemical characteristics than BSE adapted to this porcine mouse model. Altogether these data indicate.


(i) the unsuspected potential abilities of atypical scrapie to cross species barriers


(ii) the possible capacity of this agent to acquire new characteristics when crossing species barrier


These findings raise some interrogation on the concept of TSE strain and on the origin of the diversity of the TSE agents and could have consequences on field TSE control measures.








Friday, February 11, 2011


Atypical/Nor98 Scrapie Infectivity in Sheep Peripheral Tissues








RESEARCH


Emerging Infectious Diseases • www.cdc.gov/eid • Vol. 17, No. 5, May 2011


Experimental Oral Transmission of Atypical Scrapie to Sheep


Marion M. Simmons, S. Jo Moore,1 Timm Konold, Lisa Thurston, Linda A. Terry, Leigh Thorne, Richard Lockey, Chris Vickery, Stephen A.C. Hawkins, Melanie J. Chaplin, and John Spiropoulos


To investigate the possibility of oral transmission of atypical scrapie in sheep and determine the distribution of infectivity in the animals’ peripheral tissues, we challenged neonatal lambs orally with atypical scrapie; they were then killed at 12 or 24 months. Screening test results were negative for disease-specifi c prion protein in all but 2 recipients; they had positive results for examination of brain, but negative for peripheral tissues. Infectivity of brain, distal ileum, and spleen from all animals was assessed in mouse bioassays; positive results were obtained from tissues that had negative results on screening. These fi ndings demonstrate that atypical scrapie can be transmitted orally and indicate that it has the potential for natural transmission and iatrogenic spread through animal feed. Detection of infectivity in tissues negative by current surveillance methods indicates that diagnostic sensitivity is suboptimal for atypical scrapie, and potentially infectious material may be able to pass into the human food chain.


SNIP...


Although we do not have epidemiologic evidence that supports the effi cient spread of disease in the fi eld, these data imply that disease is potentially transmissible under fi eld situations and that spread through animal feed may be possible if the current feed restrictions were to be relaxed. Additionally, almost no data are available on the potential for atypical scrapie to transmit to other food animal species, certainly by the oral route. However, work with transgenic mice has demonstrated the potential susceptibility of pigs, with the disturbing fi nding that the biochemical properties of the resulting PrPSc have changed on transmission (40). The implications of this observation for subsequent transmission and host target range are currently unknown.


How reassuring is this absence of detectable PrPSc from a public health perspective? The bioassays performed in this study are not titrations, so the infectious load of the positive gut tissues cannot be quantifi ed, although infectivity has been shown unequivocally. No experimental data are currently available on the zoonotic potential of atypical scrapie, either through experimental challenge of humanized mice or any meaningful epidemiologic correlation with human forms of TSE. However, the detection of infectivity in the distal ileum of animals as young as 12 months, in which all the tissues tested were negative for PrPSc by the currently available screening and confi rmatory diagnostic tests, indicates that the diagnostic sensitivity of current surveillance methods is suboptimal for detecting atypical scrapie and that potentially infectious material may be able to pass into the human food chain undetected.


Emerging Infectious Diseases • www.cdc.gov/eid • Vol. 17, No. 5, May 2011








why do we not want to do TSE transmission studies on chimpanzees $





5. A positive result from a chimpanzee challenged severly would likely create alarm in some circles even if the result could not be interpreted for man. I have a view that all these agents could be transmitted provided a large enough dose by appropriate routes was given and the animals kept long enough. Until the mechanisms of the species barrier are more clearly understood it might be best to retain that hypothesis.


snip...


R. BRADLEY








1: J Infect Dis 1980 Aug;142(2):205-8


Oral transmission of kuru, Creutzfeldt-Jakob disease, and scrapie to nonhuman primates.


Gibbs CJ Jr, Amyx HL, Bacote A, Masters CL, Gajdusek DC.


Kuru and Creutzfeldt-Jakob disease of humans and scrapie disease of sheep and goats were transmitted to squirrel monkeys (Saimiri sciureus) that were exposed to the infectious agents only by their nonforced consumption of known infectious tissues. The asymptomatic incubation period in the one monkey exposed to the virus of kuru was 36 months; that in the two monkeys exposed to the virus of Creutzfeldt-Jakob disease was 23 and 27 months, respectively; and that in the two monkeys exposed to the virus of scrapie was 25 and 32 months, respectively. Careful physical examination of the buccal cavities of all of the monkeys failed to reveal signs or oral lesions. One additional monkey similarly exposed to kuru has remained asymptomatic during the 39 months that it has been under observation.


snip...


The successful transmission of kuru, Creutzfeldt-Jakob disease, and scrapie by natural feeding to squirrel monkeys that we have reported provides further grounds for concern that scrapie-infected meat may occasionally give rise in humans to Creutzfeldt-Jakob disease.


PMID: 6997404








Recently the question has again been brought up as to whether scrapie is transmissible to man. This has followed reports that the disease has been transmitted to primates. One particularly lurid speculation (Gajdusek 1977) conjectures that the agents of scrapie, kuru, Creutzfeldt-Jakob disease and transmissible encephalopathy of mink are varieties of a single "virus". The U.S. Department of Agriculture concluded that it could "no longer justify or permit scrapie-blood line and scrapie-exposed sheep and goats to be processed for human or animal food at slaughter or rendering plants" (ARC 84/77)" The problem is emphasised by the finding that some strains of scrapie produce lesions identical to the once which characterise the human dementias"


Whether true or not. the hypothesis that these agents might be transmissible to man raises two considerations. First, the safety of laboratory personnel requires prompt attention. Second, action such as the "scorched meat" policy of USDA makes the solution of the acrapie problem urgent if the sheep industry is not to suffer grievously.


snip...


76/10.12/4.6








Nature. 1972 Mar 10;236(5341):73-4.


Transmission of scrapie to the cynomolgus monkey (Macaca fascicularis).


Gibbs CJ Jr, Gajdusek DC.


Nature 236, 73 - 74 (10 March 1972); doi:10.1038/236073a0


Transmission of Scrapie to the Cynomolgus Monkey (Macaca fascicularis)


C. J. GIBBS jun. & D. C. GAJDUSEK


National Institute of Neurological Diseases and Stroke, National Institutes of Health, Bethesda, Maryland


SCRAPIE has been transmitted to the cynomolgus, or crab-eating, monkey (Macaca fascicularis) with an incubation period of more than 5 yr from the time of intracerebral inoculation of scrapie-infected mouse brain. The animal developed a chronic central nervous system degeneration, with ataxia, tremor and myoclonus with associated severe scrapie-like pathology of intensive astroglial hypertrophy and proliferation, neuronal vacuolation and status spongiosus of grey matter. The strain of scrapie virus used was the eighth passage in Swiss mice (NIH) of a Compton strain of scrapie obtained as ninth intracerebral passage of the agent in goat brain, from Dr R. L. Chandler (ARC, Compton, Berkshire).











Suspect symptoms


What if you can catch old-fashioned CJD by eating meat from a sheep infected with scrapie?


28 Mar 01


Like lambs to the slaughter 31 March 2001 by Debora MacKenzie Magazine issue 2284. Subscribe and get 4 free issues. FOUR years ago, Terry Singeltary watched his mother die horribly from a degenerative brain disease. Doctors told him it was Alzheimer's, but Singeltary was suspicious. The diagnosis didn't fit her violent symptoms, and he demanded an autopsy. It showed she had died of sporadic Creutzfeldt-Jakob disease.


Most doctors believe that sCJD is caused by a prion protein deforming by chance into a killer. But Singeltary thinks otherwise. He is one of a number of campaigners who say that some sCJD, like the variant CJD related to BSE, is caused by eating meat from infected animals. Their suspicions have focused on sheep carrying scrapie, a BSE-like disease that is widespread in flocks across Europe and North America.


Now scientists in France have stumbled across new evidence that adds weight to the campaigners' fears. To their complete surprise, the researchers found that one strain of scrapie causes the same brain damage in mice as sCJD.


"This means we cannot rule out that at least some sCJD may be caused by some strains of scrapie," says team member Jean-Philippe Deslys of the French Atomic Energy Commission's medical research laboratory in Fontenay-aux-Roses, south-west of Paris. Hans Kretschmar of the University of Göttingen, who coordinates CJD surveillance in Germany, is so concerned by the findings that he now wants to trawl back through past sCJD cases to see if any might have been caused by eating infected mutton or lamb.


Scrapie has been around for centuries and until now there has been no evidence that it poses a risk to human health. But if the French finding means that scrapie can cause sCJD in people, countries around the world may have overlooked a CJD crisis to rival that caused by BSE.


Deslys and colleagues were originally studying vCJD, not sCJD. They injected the brains of macaque monkeys with brain from BSE cattle, and from French and British vCJD patients. The brain damage and clinical symptoms in the monkeys were the same for all three. Mice injected with the original sets of brain tissue or with infected monkey brain also developed the same symptoms.


As a control experiment, the team also injected mice with brain tissue from people and animals with other prion diseases: a French case of sCJD; a French patient who caught sCJD from human-derived growth hormone; sheep with a French strain of scrapie; and mice carrying a prion derived from an American scrapie strain. As expected, they all affected the brain in a different way from BSE and vCJD. But while the American strain of scrapie caused different damage from sCJD, the French strain produced exactly the same pathology.


"The main evidence that scrapie does not affect humans has been epidemiology," says Moira Bruce of the neuropathogenesis unit of the Institute for Animal Health in Edinburgh, who was a member of the same team as Deslys. "You see about the same incidence of the disease everywhere, whether or not there are many sheep, and in countries such as New Zealand with no scrapie." In the only previous comparisons of sCJD and scrapie in mice, Bruce found they were dissimilar.


But there are more than 20 strains of scrapie, and six of sCJD. "You would not necessarily see a relationship between the two with epidemiology if only some strains affect only some people," says Deslys. Bruce is cautious about the mouse results, but agrees they require further investigation. Other trials of scrapie and sCJD in mice, she says, are in progress.


People can have three different genetic variations of the human prion protein, and each type of protein can fold up two different ways. Kretschmar has found that these six combinations correspond to six clinical types of sCJD: each type of normal prion produces a particular pathology when it spontaneously deforms to produce sCJD.


But if these proteins deform because of infection with a disease-causing prion, the relationship between pathology and prion type should be different, as it is in vCJD. "If we look at brain samples from sporadic CJD cases and find some that do not fit the pattern," says Kretschmar, "that could mean they were caused by infection."


There are 250 deaths per year from sCJD in the US, and a similar incidence elsewhere. Singeltary and other US activists think that some of these people died after eating contaminated meat or "nutritional" pills containing dried animal brain. Governments will have a hard time facing activists like Singeltary if it turns out that some sCJD isn't as spontaneous as doctors have insisted.


Deslys's work on macaques also provides further proof that the human disease vCJD is caused by BSE. And the experiments showed that vCJD is much more virulent to primates than BSE, even when injected into the bloodstream rather than the brain. This, says Deslys, means that there is an even bigger risk than we thought that vCJD can be passed from one patient to another through contaminated blood transfusions and surgical instruments.







Monday, December 14, 2009


Similarities between Forms of Sheep Scrapie and Creutzfeldt-Jakob Disease Are Encoded by Distinct Prion Types


(hmmm, this is getting interesting now...TSS)


Sporadic CJD type 1 and atypical/ Nor98 scrapie are characterized by fine (reticular) deposits,


see also ;


All of the Heidenhain variants were of the methionine/ methionine type 1 molecular subtype.






see full text ;


Monday, December 14, 2009


Similarities between Forms of Sheep Scrapie and Creutzfeldt-Jakob Disease Are Encoded by Distinct Prion Types







Friday, March 09, 2012


Experimental H-type and L-type bovine spongiform encephalopathy in cattle: observation of two clinical syndromes and diagnostic challenges


Research article







Thursday, June 23, 2011


Experimental H-type bovine spongiform encephalopathy characterized by plaques and glial- and stellate-type prion protein deposits








Thursday, February 14, 2013


*** The Many Faces of Mad Cow Disease Bovine Spongiform Encephalopathy BSE and TSE prion disease








Tuesday, March 5, 2013


Use of Materials Derived From Cattle in Human Food and Cosmetics; Reopening of the Comment Period FDA-2004-N-0188-0051 (TSS SUBMISSION)


FDA believes current regulation protects the public from BSE but reopens comment period due to new studies







Tuesday, March 05, 2013


A closer look at prion strains Characterization and important implications


Prion 7:2, 99–108; March/April 2013; © 2013 Landes Bioscience








Tuesday, May 28, 2013


Late-in-life surgery associated with Creutzfeldt-Jakob disease: a methodological outline for evidence-based guidance








Thursday, May 30, 2013


World Organization for Animal Health (OIE) has upgraded the United States' risk classification for mad cow disease to "negligible" from "controlled", and risk further exposing the globe to the TSE prion mad cow type disease


U.S. gets top mad-cow rating from international group and risk further exposing the globe to the TSE prion mad cow type disease































TSS





Thursday, May 30, 2013

Statement from Agriculture Secretary Tom Vilsack Regarding World Organization for Animal Health (OIE) Upgrade of United States' BSE Risk Status

Release No. 0106.13 Contact: USDA Office of Communications (202) 720-4623



Statement from Agriculture Secretary Tom Vilsack Regarding World Organization for Animal Health (OIE) Upgrade of United States' BSE Risk Status



WASHINGTON, May 29, 2013–Agriculture Secretary Tom Vilsack made the following statement about notification received today from the World Organization for Animal Health (OIE) upgrading the United States' risk classification for bovine spongiform encephalopathy (BSE) to negligible risk: "I am very pleased with OIE's decision to grant the United States negligible risk status for BSE. This is a significant achievement that has been many years in the making for the United States, American beef producers and businesses, and federal and state partners who work together to maintain a system of interlocking safeguards against BSE that protect our public and animal health. This decision demonstrates OIE's belief that both our surveillance for, and safeguards against, BSE are strong. U.S. beef and beef products are of the highest quality, wholesome and produced to the highest safety standards in the world. Last year, exports of U.S.-origin beef and beef products totaled $5.5 billion. With our negligible risk classification from the OIE, we have a strong foundation in place to continue increasing exports of U.S.-origin beef and beef products. In doing so, we will continue to press trading partners to base their decisions on science, consistent with international standards. U.S. food and agricultural exporters and consumers worldwide benefit when countries adopt science-based international standards." #


USDA is an equal opportunity provider and employer. To file a complaint of discrimination, write: USDA, Office of the Assistant Secretary for Civil Rights, Office of Adjudication, 1400 Independence Ave., SW, Washington, DC 20250-9410 or call (866) 632-9992 (Toll-free Customer Service), (800) 877-8339 (Local or Federal relay), (866) 377-8642 (Relay voice users).












the new BSE TSE PRION MAD COW risk category the OIE gave the USA, puts everyone around the globe at more risk of a tse prion mad cow type disease now.


in my opinion, this new risk category was bought and paid for by your local cattle dealer, via fraud.


IT is of my opinion, that the OIE and the USDA et al, are the soul reason, and responsible parties, for Transmissible Spongiform Encephalopathy TSE prion diseases, including typical and atypical BSE, typical and atypical Scrapie, and all strains of CWD, and human TSE there from, spreading around the globe.


I have lost all confidence of this organization as a regulatory authority on animal disease, and consider it nothing more than a National Trading Brokerage for all strains of animal TSE, just to satisfy there commodity. AS i said before, OIE should hang up there jock strap now, since it appears they will buckle every time a country makes some political hay about trade protocol, commodities and futures. IF they are not going to be science based, they should do everyone a favor and dissolve there organization.


JUST because of low documented human body count with nvCJD and the long incubation periods, the lack of sound science being replaced by political and corporate science in relations with the fact that science has now linked some sporadic CJD with atypical BSE and atypical scrapie, and the very real threat of CWD being zoonosis, I believed the O.I.E. has failed terribly and again, I call for this organization to be dissolved. ...




IN A NUT SHELL ;


(Adopted by the International Committee of the OIE on 23 May 2006)


11. Information published by the OIE is derived from appropriate declarations made by the official Veterinary Services of Member Countries. The OIE is not responsible for inaccurate publication of country disease status based on inaccurate information or changes in epidemiological status or other significant events that were not promptly reported to the Central Bureau,







i pulled this comment off another board about the OIE and all it's lobby groups. please see ;



Having been to their offices in Paris and talked personally with the Head of the Animal Test Section, you would choke if you knew how many lobby groups attend that office daily. There is a steady stream of paid lobby groups that have one goal in life and that is to sway the Section Heads of each department within the OIE to suit the needs of different juristictions around the world, which curiously enough, also includes the USA and Canada. Anyone can go there and chat with them - providing they can privide valid cause to be let in. To say that the only goal of the OIE is animal health is actually only part of their function. They are more than that and my discussions with Dr. Diaz there has showed me that. But to blindly make a statement regarding what they do when you have no idea what they actually do is like eating the skin of the orange and not knowing what is actually under. Interstingly you state that the US Government applied pressure (to the OIE) I assume and that is a great example of the lobby groups doing their job. So, at the end of the day, one can safely assume that it is the pressure applied by certain influential lobby groups that will determine a likely aoutcome to an apparent OIE directive. Man alive, isn't it great to live in a democracy wherein the people get to make the choices and not just some "other" interested party or group - say like........Cargyll or Tyson for example?



So, one last question, question?



Who wags the tail of that dog?? And for what reason other than one that is purely associated with trade and international agreements and greed?



Location: Edmonton, Alberta, Canada



Occupation: CEO of BSE Prion Solutions Inc.



Interests: Prion Diseases and Live Animal Testing



end...tss





please see history of the USDA, OIE, mad cow follies and cover up and fraud there from here ;




Thursday, May 30, 2013







World Organization for Animal Health (OIE) has upgraded the United States' risk classification for mad cow disease to "negligible" from "controlled", and risk further exposing the globe to the TSE prion mad cow type disease







U.S. gets top mad-cow rating from international group







and risk further exposing the globe to the TSE prion mad cow type disease












Tuesday, May 21, 2013



Canada, USA, Bad feed, mad cows: Why we know three BSE cases had a common origin and why the SSS policy is in full force $$$








Tuesday, May 7, 2013



Feds want five-year paper trail for livestock NAIS COOL








Friday, April 19, 2013




APHIS 2013 Stakeholder Meeting (March 2013) BSE TSE PRION











Wednesday, February 20, 2013


World Organization for Animal Health Recommends United States' BSE Risk Status Be Upgraded

Statement from Agriculture Secretary Tom Vilsack:





http://madcowusda.blogspot.com/2013/02/world-organization-for-animal-health.html





 



Thursday, February 14, 2013



The Many Faces of Mad Cow Disease Bovine Spongiform Encephalopathy BSE and TSE prion disease




http://bse-atypical.blogspot.com/2013/02/the-many-faces-of-mad-cow-disease.html










Monday, October 10, 2011

EFSA Journal 2011 The European Response to BSE: A Success Story
 


snip...
 


EFSA and the European Centre for Disease Prevention and Control (ECDC) recently delivered a scientific opinion on any possible epidemiological or molecular association between TSEs in animals and humans (EFSA Panel on Biological Hazards (BIOHAZ) and ECDC, 2011). This opinion confirmed Classical BSE prions as the only TSE agents demonstrated to be zoonotic so far but the possibility that a small proportion of human cases so far classified as "sporadic" CJD are of zoonotic origin could not be excluded. Moreover, transmission experiments to non-human primates suggest that some TSE agents in addition to Classical BSE prions in cattle (namely L-type Atypical BSE, Classical BSE in sheep, transmissible mink encephalopathy (TME) and chronic wasting disease (CWD) agents) might have zoonotic potential.
 
 

snip...


 

 



 


 






Thursday, August 12, 2010
 

Seven main threats for the future linked to prions
 


First threat
 


The TSE road map defining the evolution of European policy for protection against prion diseases is based on a certain numbers of hypotheses some of which may turn out to be erroneous. In particular, a form of BSE (called atypical Bovine Spongiform Encephalopathy), recently identified by systematic testing in aged cattle without clinical signs, may be the origin of classical BSE and thus potentially constitute a reservoir, which may be impossible to eradicate if a sporadic origin is confirmed.
 

***Also, a link is suspected between atypical BSE and some apparently sporadic cases of Creutzfeldt-Jakob disease in humans. These atypical BSE cases constitute an unforeseen first threat that could sharply modify the European approach to prion diseases.
 


Second threat
 


snip...

 












Tuesday, March 05, 2013


A closer look at prion strains Characterization and important implications Prion

7:2, 99–108; March/April 2013; © 2013 Landes Bioscience



http://creutzfeldt-jakob-disease.blogspot.com/2013/03/a-closer-look-at-prion-strains.html










http://creutzfeldt-jakob-disease.blogspot.com/








TSS









Terry S. Singeltary Sr.


P.O. Box 42


Bacliff, Texas USA 77518


Friday, May 24, 2013

Asynchronous Onset of Clinical Disease in BSE-Infected Macaques

Volume 19, Number 7—July 2013


Dispatch



Asynchronous Onset of Clinical Disease in BSE-Infected Macaques



Judith Montag1, Walter Schulz-Schaeffer, Annette Schrod, Gerhard Hunsmann, and Dirk Motzkus Author affiliations: German Primate Center, Göttingen, Germany (J. Montag, A. Schrod, G. Hunsmann, D. Motzkus); University of Göttingen, Göttingen (W. Schulz-Schaeffer)




Abstract



To estimate the effect of the variability of prion disease onset on primary bovine spongiform encephalopathy transmission to humans, we studied 6 cynomolgus macaques. The preclinical incubation period was significantly prolonged in 2 animals, implying that onset of variant Creutzfeldt-Jacob disease in humans could be more diverse than previously expected.




Prion diseases, such as bovine spongiform encephalopathy (BSE) in cattle, scrapie in sheep, and Creutzfeldt-Jakob disease (CJD) in humans, are fatal, transmissible, neurodegenerative disorders associated with the aggregation of an infectivity-associated isoform (PrPSc) of the cellular prion protein (PrP) (1). Seventeen years ago, it became apparent that the BSE-infectious agent had entered the food chain and was identified as the causative agent for a new variant CJD (vCJD) (2). Since then, several risk assessment studies have investigated the number of expected vCJD cases in human populations (reviewed in [3]). Although thousands to millions of consumers of beef products were estimated to be affected, thus far only a few more than 200 vCJD cases have been observed worldwide.




This discrepancy was assumed to be attributable to the so-called species barrier, defined as the hindrance of an infectious agent to change its natural host. Upon crossing the species barrier, prion diseases often show a low attack rate in conjunction with a high variability in the preclinical incubation time. Thus, the consumption of BSE-contaminated products may have led either to a restricted infection or to a prolonged asymptomatic phase in some exposed persons. Therefore, concerns have been raised that asymptomatic carriers of vCJD might exist, posing a risk for unintentional human-to-human transmission.




First indications that transmission of BSE to primates may lead to variances in the preclinical incubation times were obtained by inoculating cynomolgus macaques with cattle-derived BSE material (4–6), even though in those studies not more than 3 animals were used. We have now used a group of 6 macaques that were infected with BSE at a comparable age and kept under identical and controlled experimental conditions.




The Study Six captive-bred female cynomolgus macaques (Macaca fascicularis, purchased from the Centre de Recherche en Primatologie, Mauritius) were inoculated intracerebrally with 1 dose of 50 mg brain homogenate (10% wt/vol) derived from 11 BSE-infected cattle. Animal experimentation was performed in accordance with section 8 of the German Animal Protection Law in compliance with Directive 86/609/EEC. Macaques were housed in a social group, and behavioral changes were assessed on a daily basis by experienced animal care takers.




After inoculation, all 6 macaques remained healthy and asymptomatic for >30 months (Table). At 931 days postinfection, 1 animal showed indications of slight coordination disorders. Within a few days, afferent ataxia developed, and when the animal was separated from the others animals, she apparently became tame. After 2 weeks, the animal showed severe dysmetria of the extremities without obvious myoclonia. Dementia was apparent but could not be diagnosed by objective measures. For ethical reasons, the animal was euthanized 17 days after disease onset. Within the next 14 weeks, 3 more animals became symptomatic. After appearance of neurologic symptoms (ataxia, tremors), the affected animals were occasionally separated from the group when symptoms became more severe or attacks from asymptomatic animals occurred. The disease course in these animals was comparable to that of the first animal, but the progression was slower (91–103 days).




Figure 1




Figure 1. . Survival of intracerebrally BSE-infected cynomolgus macaques. Six age- and sex-matched cynomolgus macaques were inoculated intracerebrally with 50 mg brain homogenate (10% in sucrose) derived from 11 BSE-infected cattle. Macaques were...




Two of the 6 animals remained asymptomatic for ≈1 additional year. Although daily monitoring was facilitated by the fact that only 2 macaques remained and that the caretakers were more experienced to recognize minor changes in behavior, symptoms were first detected 1,340 and 1,398 days postinfection, respectively. Clinical signs were similar to those observed in the previous 4 animals. The symptomatic periods before euthanasia for these macaques lasted 103 and 143 days, respectively (Table). Direct comparison revealed that the difference between the short (931–1,025 days) and the long (1,340–1,398 days) preclinical incubation time was statistically significant (Figure 1, log-rank [Mantel-Cox] test, p<0 .05="" div="">



Test results of brain samples from all animals were positive for macaque-adapted BSE by Western blot analysis. In brief, brain tissue from each animal was homogenized and subjected to proteinase K (PK) treatment for 1 h at 37°C. Samples were separated on acrylamide gels and transferred to nitrocellulose membranes. Macaque-adapted BSE (PrPSc) was detected by using the monoclonal anti-PrP antibody 11C6. PK-resistant PrP was detected in all 6 macaques, confirming that BSE was transmitted to the animals.




Figure 2



Figure 2. . PrPSc profile of macaque-adapted BSE in comparison to human CJD. Brain homogenates from human sCJD type 1, sCJD type 2, vCJD, and BSE-infected macaques were subjected to PK treatment, separated...




The individual glycopattern and band migration of macaque-adapted PrPSc was compared with human sporadic CJD (sCJD) type 1, sCJD type 2, and vCJD. PK-resistant PrP from BSE-infected macaques co-migrated with type 2 sCJD and was clearly distinguishable from type 1 sCJD (Figure 2). The glycosylation pattern of macaque-adapted BSE was comparable with vCJD (6,7), which is characterized by an overrepresentation of diglycosylated PrPSc (8,9). Using 11C6 antibody (10), we detected a slightly decreased signal of the diglycosylated PrPSc isoform for sCJD, vCJD, and macaque-adapted BSE. We assume that this effect is related to a reduced affinity of the diglycosylated isoform to 11C6 that otherwise shows high sensitivity to macaque-adapted PrPSc. Nevertheless, direct comparison showed a higher amount of the diglysosylated PrPSc isoform in vCJD and macaque-adapted BSE than sCJD, which was also shown with a different monoclonal antibody, 3F4. This finding confirms that BSE transmission to macaques is comparable with, and can be used as a model for, human vCJD infection.




Conclusions




Several susceptibility studies using nonhuman primates as a model for human prion diseases hint to heterogeneity of the preclinical incubation period upon crossing the species barrier (5,11,12). However, because of the low number of no more than 3 animals, this variability was not always evident (4). Therefore, there was an urgent need to determine whether the transmission of BSE to humans is likely to lead to a similar diversity.




Our study using 6 cynomolgus macaques shows that the transmission of BSE to primates led to a significantly prolonged asymptomatic phase in 2 animals. Disease onset is influenced by several factors (13). Our study design enabled us to exclude that the route of transmission influenced the disease progression because the infectious agent was injected into the same brain region of each animal. Also, a limited infectious dose cannot be responsible, as shown by the attack rate of 100%. In addition, endogenous factors, such as age, the MM genotype at codon 129 (Table), and housing conditions, were comparable for all macaques.




Thus, we conclude that the variable asymptomatic phase is most likely influenced by the infectious agent (14) or the genomic diversity of the macaques (13). The animals in our study were not inbred. Therefore, differences in the genomic background may have influenced the time of disease onset. In contrast, the PrPSc migration patterns of the animals give no indications for different types or strains that evolved from the mixed BSE inoculum. However, further studies will have to verify this.




Nevertheless, during the BSE epidemics, the human population with its natural genomic diversity was also exposed to a nonhomogenous prion source. Therefore, our study closely mimics the human situation. Our results imply that a prolonged asymptomatic phase can be expected for vCJD. In light of the transmissibility of vCJD through blood transfusions (15), our findings emphasize the need for continued attention to the risks of secondary human-to-human transmission.




Dr Montag is a microbiologist at the Department of Molecular and Cell Physiology at the Hannover Medical School. Her primary research interests are the molecular mechanisms of disease pathology, including prion disorders and inherited cardiac diseases.




Acknowledgments We thank J.P. Deslys for providing vCJD material.




This study was supported by European Union grant QLK1-CT-2002-01096 and BMH4-CT-98-6029.




References




snip...see full text ;








Monday, October 10, 2011


EFSA Journal 2011 The European Response to BSE: A Success Story


snip...


EFSA and the European Centre for Disease Prevention and Control (ECDC) recently delivered a scientific opinion on any possible epidemiological or molecular association between TSEs in animals and humans (EFSA Panel on Biological Hazards (BIOHAZ) and ECDC, 2011). This opinion confirmed Classical BSE prions as the only TSE agents demonstrated to be zoonotic so far but the possibility that a small proportion of human cases so far classified as "sporadic" CJD are of zoonotic origin could not be excluded. Moreover, transmission experiments to non-human primates suggest that some TSE agents in addition to Classical BSE prions in cattle (namely L-type Atypical BSE, Classical BSE in sheep, transmissible mink encephalopathy (TME) and chronic wasting disease (CWD) agents) might have zoonotic potential.



snip...













Thursday, August 12, 2010



Seven main threats for the future linked to prions



First threat



The TSE road map defining the evolution of European policy for protection against prion diseases is based on a certain numbers of hypotheses some of which may turn out to be erroneous. In particular, a form of BSE (called atypical Bovine Spongiform Encephalopathy), recently identified by systematic testing in aged cattle without clinical signs, may be the origin of classical BSE and thus potentially constitute a reservoir, which may be impossible to eradicate if a sporadic origin is confirmed.



***Also, a link is suspected between atypical BSE and some apparently sporadic cases of Creutzfeldt-Jakob disease in humans. These atypical BSE cases constitute an unforeseen first threat that could sharply modify the European approach to prion diseases.



Second threat



snip...













Tuesday, March 05, 2013


A closer look at prion strains Characterization and important implications Prion


7:2, 99–108; March/April 2013; © 2013 Landes Bioscience









Friday, April 19, 2013


APHIS 2013 Stakeholder Meeting (March 2013) BSE TSE PRION









Monday, May 6, 2013


Warning of mad cow disease threat to blood transfusions









Sunday, May 19, 2013


CJD BLOOD SCREENING, DONORS, AND SILENT CARRIERS House of Commons Written Answers 16 May 2013









Tuesday, May 21, 2013


CJD, TSE, PRION, BLOOD Abstracts of the 23rd Regional Congress of the International Society of Blood Transfusion, Amsterdam, The Netherlands, June 2-5, 2013










Sunday, February 10, 2013


Creutzfeldt-Jakob disease (CJD) biannual update (February 2013) Infection report/CJD









Saturday, December 15, 2012


Bovine spongiform encephalopathy: the effect of oral exposure dose on attack rate and incubation period in cattle -- an update 5 December 2012










Thursday, February 14, 2013


The Many Faces of Mad Cow Disease Bovine Spongiform Encephalopathy BSE and TSE prion disease










Tuesday, March 5, 2013


Use of Materials Derived From Cattle in Human Food and Cosmetics; Reopening of the Comment Period FDA-2004-N-0188-0051 (TSS SUBMISSION)


FDA believes current regulation protects the public from BSE but reopens comment period due to new studies









Tuesday, November 02, 2010


BSE - ATYPICAL LESION DISTRIBUTION (RBSE 92-21367) statutory (obex only) diagnostic criteria CVL 1992











Wednesday, April 24, 2013


Chimpanzees Released After 30 Years Of Testing, Brace Yourself For Smiles









TSS

Tuesday, May 21, 2013

CJD, TSE, PRION, BLOOD Abstracts of the 23rd Regional Congress of the International Society of Blood Transfusion, Amsterdam, The Netherlands, June 2-5, 2013

Abstracts of the 23rd Regional Congress of the International Society of Blood Transfusion, Amsterdam, The Netherlands, June 2-5, 2013 Oral Abstracts Oral Abstracts (pages 1–64) Article first published online: 20 MAY 2013 | DOI: 10.1111/vox.12047





1D-H08-02




CURRENT PERSPECTIVES IN TRANSFUSION-TRANSMITTED INFECTIOUS DISEASES: EMERGING AND IMPORTED INFECTIONS, INCLUDING PARASITES


Stramer SL


American Red Cross, Gaithersburg, MD, United States of America


Background: In August 2009, a group from the AABB (Stramer et al., Transfusion 2009;99:1S-29S, Emerging Infectious Disease Agents and their Potential Threat to Transfusion Safety; http://www.aabb.org/resources/bct/eid/Pages/default.aspx) published a Supplement to Transfusion that reviewed the definition and background of emerging infectious disease (EID) agents that pose a real or theoretical threat to transfusion safety, but for which an existing effective intervention is lacking. The necessary attributes for transfusion transmission were outlined including: presence of the agent in blood during an asymptomatic phase in the donor, the agent’s survival/ persistence in blood during processing/storage, and lastly that the agent must be recognized as responsible for a clinically apparent outcome in at least a proportion of recipients who become infected. Without these attributes, agents are not considered as a transfusion-transmission threat and were excluded. Sixty-eight such agents were identified with enough evidence/likelihood of transfusion transmission (e.g. blood phase) and potential for clinical disease to warrant further consideration. In the Supplement, Fact Sheets (FS) were published providing information on: agent classification; background on the disease agent’s importance; the clinical syndromes/ diseases caused; transmission modes (including vectors/reservoirs); likelihood of transfusion transmission, and if proven to be transfusion transmitted, information on known cases; the feasibility and predicted success of interventions that could be used donor screening (questioning) and tests available for diagnostics or that could be adapted for donor screening; and finally, the efficacy, if known, of inactivation methods for plasma-derived products. The Supplement also included a separate section on pathogen reduction technologies for all blood components using published data.
 
 
Agents were prioritized relative to their scientific/epidemiologic threat as well as their perceived threat to the community including concerns expressed by the regulators of blood.
 
 
Agents given the highest priority due to a known transfusiontransmission threat and severe/fatal disease in recipients were the vCJD prion, dengue viruses and the obligate red-cell parasite that causes babesiosis (B. microti and related babesia).
 
 
Although the focus of the Supplement was towards the United States and Canada, many of the agents (and the process) are applicable worldwide. Next steps: Since the publication of the Supplement, five new FSs (yellow fever viruses-including vaccine breakthrough infections, miscellaneous arboviruses, XMRV-including a comprehensive table of published literature, and human parvoviruses/ bocaviruses other than B19) were added and 11 existing FSs updated (babesia, bartonella, chronic wasting disease-CWD, human prions other than vCJD, vCJD, Coxiella burnetii-the agent of Q fever, dengue viruses, HEV, Japanese encephalitis- JE complex, tick-borne encephalitis viruses-TBEV, and human parvovirus B19). Also, tables were released outlining pathogen reduction clinical trials/results (published) and availability/commercial routine use of such technologies by country for platelets, plasma, red cells and whole blood. Of necessity, the list of EID agents is not, and can never be, exhaustive due to the nature of emergence. We recognized that a system of assessing the risk/threat of EIDs for their potential impact on blood safety and availability must include a process for monitoring, identification, evaluation, estimating severity, risk assessments and intervention development. Thus, we are now developing a ‘toolkit’ containing the necessary ‘tools’ from EID monitoring (horizon scanning) to validation/effectiveness evaluations of interventions. Our goal is, ‘to develop a systematic approach to risk assessment and intervention development for the impact of emerging infectious upon blood safety in North America. The system is primarily intended to educate and advise AABB members about risks and interventions in a timely and accurate fashion. Secondary audiences include North American blood systems, blood services and transfusion services’. Certainly this toolkit may be adapted to the needs of ISBT members. Conclusions: The process and final product (toolkit) including methods to monitor EID agent emergence, identification/recognition of a transfusion-transmission threat, methods for quantitative risk assessments, and the appropriate management of such threats should be considered for implementation by all blood systems.






3B-PL6


EVALUATION OF NEURODEGENERATIVE DISEASES AS A THREAT TO THE BLOOD SUPPLY


Edgren G1,2 1Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden 2Department of Hematology, Karolinska University Hospital, Stockholm, Sweden


Background: During recent years, evidence has been accumulating that protein misfolding is central in the causation of a range of neurodegenerative disorders, including Alzheimer’s disease (AD) and Parkinson’s disease (PD). Considering for example AD, where one of the hallmark features is the aggregation of aberrantly misfolded proteins in the brain, which seems to propagate through the brain in an infectionlike process. Similar observations have been made for Parkinson’s disease, where intrastriatal inoculation of misfolded a-Synuclein – the principal component of Lewy bodies – initiates Parkinson-like neurodegeneration in mice. Similarities with prion diseases have been noted. This is especially disconcerting in light of evidence that variant Creutzfeldt-Jakob disease (vCJD), which could also be characterized as a misfolded protein disease, is transfusion transmittable in sheep – even with blood taken during the symptom free phase of infection – and might have been transmitted by transfusions in humans. As such, the possibility of transfusion transmission of several neurodegenerative disorders is a relevant concern. Aims: To investigate the possible consequences for the blood supply, we assessed the occurrence of a selected range of neurodegenerative diseases in Scandinavian blood donors and possible transfusion transmission of AD.


Methods: The analyses were all based on the Scandinavian donations and transfusions (SCANDAT) database which records the entire computerized blood donation and transfusion history in Sweden and Denmark. We identified all blood donors who had performed at least one whole blood, plasma or platelet donation between 1968 and 2002, and their respective transfusion recipients. Data on donors and transfused patients was linked with national inpatient and cause of death registers to ascertain the occurrence of AD, PD, Amyotrophic lateral sclerosis (ALS) and Dementia of any type. The probability that a particular donation was made by a donor who later developed one of these disorders within 10, 20 or 25 years, was estimated as cumulative incidences using the Kaplan–Meier method. Follow-up was extended until death, emigration or end of follow-up. We also investigated possible transmission of AD by comparing the incidence of AD in recipients of blood from donors who went on to develop AD and recipients of blood from donors who did not develop AD. Transmission analyses were adjusted for necessary confounding factors.


Results: In all, we included 1.1 million blood donors, followed over 13 million person years. A total of 730 donors developed AD, 827 PD, 338 ALS and 2418 Dementia. The probability that a donation was made by a donor who developed AD within 10, 20 and 25 years was 0.03%, 0.19% and 0.45%. For PD, probabilities were 0.03%, 0.22% and 0.45%, and for ALS, 0.02%, 0.07%, and 0.11%. For Dementia, estimates were 0.08%, 0.63%, and 1.44%. Finally, there was no evidence of AD transmission (relative risk, 1.00; 95% CI, 0.78–1.28)


Conclusions: Even when considering latencies as long as 25 years, very few donations are made by donors who go on to develop a neurodegenerative disease. Importantly, we see no association between AD occurrence in donors and their respective recipients, indicating that such transmission is unlikely.




Donor Health and Safey – Infectious Uncertainties





3D-S26-01


AN AMPLIFICATION ASSAY FOR THE PRESYMPTOMATIC DETECTION OF PRION IN BLOOD


Segarra C1, Bougard D1, Beringue V2 and Coste J1 1Etablissement Francais du Sang Pyr en ees-M editerran ee R&D TransDiag, Montpellier, France 2UR892 VIM, Institut National de Recherche Agronomique, Jouy-en-Josas, France


Background: Prion diseases or Transmissible Spongiform Encephalopathies (TSEs) are neurodegenerative diseases including the variant of Creutzfeldt-Jakob disease (vCJD) in humans. The central event of these diseases would be the conformational change of a normal cellular protein PrPC into an infectious form PrPTSE. It is now evident that TSEs are transmissible by blood transfusion and this has raised concerns that a reservoir of infectious asymptomatic people could exist in the blood donor population. Until now, no screening test could detect the infectious agent in blood before the onset of clinical signs of disease.


Aims: The objective of this study is to develop a sensitive and specific test that enables the detection of PrPTSE in the blood during the presymptomatic phase of TSE.


Methods: The detection assay comprises three major steps: (i) a ligand-coated bead pre-analytical step in order to concentrate PrPTSE from the different blood components and to remove inhibitory factors which can interfere in the amplification; (ii) a PrPTSE amplification by serial PMCA using transgenic mouse brain homogenate as substrate and (iii) a specific detection of the amplified PrPTSE by immuno-blotting after partial proteinase K digestion. The sample volume has been optimized for 500 ll of plasma and for 25–50 ll of buffy-coat. Whole blood samples from infected sheep collected during preclinical and clinical phases of scrapie were processed in buffy-coat, white blood cells (WBC) and plasma.


Results: PMCA assay allowed detection of PrPTSE in: (i) the WBC of four sheep at the acute phase of scrapie with a 100% sensitivity and specificity, (ii) in the plasma and buffy coat collected in the asymptomatic phase of the disease. Summary/Conclusions: The expected level of sensitivity for the detection of prion in the blood was reached. This assay is currently evaluated as a confirmatory detection test for the presence of the vCJD agent in human blood. The next step will be to perform prevalence studies by analysing panels of at-risk populations.










Poster Abstracts Poster Abstracts (pages 65–299)


Article first published online: 20 MAY 2013 | DOI: 10.1111/vox.12048






P-368


IS ALZHEIMER’S DISEASE A PRION DISEASE?


Segarra C and Coste J


Etablissement Francais du Sang Pyr en ees-M editerran ee R&D TransDiag, Montpellier, France


Alzheimer’s disease (AD) is the most common type of senile dementia, mainly affecting individuals over 65 years old. Disease manifestation is characterized by progressive impairment of memory and cognition, mainly produced by synaptic dysfunction and neuronal loss. This fatal neurodegenerative disease is a matter of great interest because since its first description in 1906 by the psychiatrist A. Alzheimer the AD cases doesn’t stop to increase and more than 90% of disease arise sporadically. Cerebral accumulation of misfofded protein aggregates composed of amyloid b (Ab) proteins and hyperphosphorylated tau protein have been associated to the disease. In the past decade, there has been renewed interest in the possibility that the proteins causing neurodegenerative disorders are all prions. Recently, the origin of the disease, described until now as linked to aging, was re-evaluated by S. Prusiner (Nobel Prize). In animal models he has shown that, when the neurodegenerative process had been started, it propagates over all the brain, by a prion-like mechanism – prion is the responsible agent of Transmissible Spongiform Encephalopathy (TSE) such as Creutzfeldt-Jacob Disease (CJD).


The misfolding and aggregation mechanisms and structural intermediates are very similar in both AD and TSE. The starting point would be a normal protein, PrPC (Cellular Prion) for TSE and APP (Amyloid Precursor Protein) for AD, which would be converted into pathological misfolded proteins (MFP): PrPSc (scrapie Prion) and Ab protein respectively. These MFP would be then implicated in a process of selfaggregation, leading to the formation of amyloid plaques in the brain. Moreover the mechanism of aggregation follows the same seeding-nucleation process.


Several studies in animal models had shown that:


1 For TSE, the PrPSc aggregates generated by this process were infectious.


2 Ab deposition can be induced by injection of AD brain extracts into animals which without exposure to this material will never develop brain alterations.


3 The transfusion of blood from mice with amyloid plaques in brain accelerates the neuro-degenerative phenomenon and the memory loss in two different models of healthy transgenic mice.


In conclusion, questions on the infectivity of Ab protein in Alzheimer’s disease and the possible secondary transmission by blood transfusion are posed.






P-382


REMOVAL OF EXOGENOUS PRION INFECTIVITY IN LEUCOREDUCED RED BLOOD CELLS UNIT BY P-CAPTTM PRION REMOVAL FILTER


Lescoutra N1, Sumian C1, Culeux A1, Durand V2, Deslys JP2 and Comoy EE2 1MacoPharma, Fontenay-aux-Roses, France 2CEA, Prion Research Group, DSV/ IMETI/SEPIA, Fontenay-aux-Roses, France


Background: Five cases of variant Creutzfeldt-Jakob Disease (vCJD) infections were probably linked to infusion of contaminated blood components, turning to real the inter-human transmissibility of this prion disease from asymptomatic carriers. Corresponding preventive policies are currently limited to exclusion from blood donation, but also take advantage of leucoreduction initially implemented against leucotropic viruses. In the absence of available antemortem diagnostic tests, the updated prevalence of silent vCJD infections (1/2000 in the UK) urges the necessity to enforce blood safety with more efficient active measures able to remove remaining infectivity.


Aims: Several affinity resins were proved to experimentally reduce high levels of brain-spiked infectivity from human leucoreduced red blood cell concentrates (L-RBC). One was integrated in a device adapted to field constraints (volumes, duration) of human transfusion. We aimed here to assess the ability of the final device, in its real conditions of use, i.e. the real conditions of filtration with human leucoreduced red cell concentrates (L-RBC), to remove infectivity from human L-RBC unit spiked with scrapie-infected hamster brain.


Methods: A standardized method for preparation of clarified brain homogenate from 263 K infected hamsters, allowing elimination of large aggregates of PrPres without modification of apparent infectivity, was selected for spiking human L-RBC unit. Filtration by gravity, according to the manufacturer’s recommendations, of a 0.0001% spiked L-RBC unit was carried out on day 1 at room temperature. Pre- and post- blood filtration sample aliquots were removed for infectivity studies (intracerebral inoculation of hamsters). Results: Incubation periods of recipient animals suggest around 3 log10 removal of brain-derived prion infectivity by filtration through the P-Capt[TRADEMARK].


Conclusion: On brain-derived spiked infectivity, the P-Capt[TRADEMARK] filter provided similar performances as columns used for initial proof-of-concept studies (Gregori et al., Lancet 2006), suggesting an appropriate scale-up to efficiently remove infectivity from an individual human blood bag. According to the ability of resin to completely remove apparent endogenous infectivity from hamster leucoreduced blood, the implementation of such a filter, now commercially available, might seriously improve blood safety towards prion.






P-383


UPDATE ON THE ABILITY OF THE PRION CAPTURE FILTER, P-CAPTTM, TO DELAY ONSET OF AN ORIGINAL MYELOPATHIC DISEASE OBSERVED IN PRIMATES EXPOSED TO PRION INFECTED BLOOD PRODUCTS


Lescoutra N1, Jaffre N2, Culeux A1, Sumian C1, Durand V2, Mikol JP2, Luccantoni S2, Deslys JP2 and Comoy EE2


1MacoPharma, Fontenay-aux-Roses, France 2CEA, Prion Research Group, DSV/ IMETI/SEPIA, Fontenay-aux-Roses, France


Background: In the United Kingdom, the recent report of four human cases of variant of Creutzfeldt-Jakob disease (vCJD) through transfusion has justified the implementation of measures to secure blood and blood products towards prions. Leucoreduction, implemented against blood-borne viruses, is not sufficient to remove the entire prion blood infectivity, halved between white cells and plasma. In absence of antemortem diagnostic tests, several devices, including P-Capt[TRADEMARK] filter, were designed to remove prions. This filter incorporates an affinity resin specific for PrP, which has already demonstrated its efficiency in removing both exogenous and endogenous prion infectivity in the experimental model of hamster infected with the experimental 263 K strain. The ability of the P-Capt [TRADEMARK] filter was also previously assessed with human L-RBC artificially contaminated with 263 K clarified brain extracts and demonstrated comparable efficiency.


Aims: We aimed to complete the evaluation of the P-Capt[TRADEMARK] filter with blood-borne infectivity in the cynomolgus macaque considered as an utmost relevant model for the investigation of human prion diseases. Methods: Two independent experiments were performed 1 year apart. First, five donor primates were intravenously (iv) inoculated with high amounts of clarified brain homogenate from a BSE-infected primate to maximize their blood infectivity. At the onset of first clinical signs, their blood was drawn and pooled to reach a volume equivalent to a human blood donation. After whole blood leucoreduction, Red Blood Cell Concentrate (L-RBC) was prepared following routine blood human procedures. L-RBC was suspended in plasma according to conditions used for pediatric transfusion in the UK. Twenty-seven milliliters were transfused to two or three recipient primates prior or after P-Capt[TRADEMARK] filtration respectively. In the second experiment designed for the evaluation of a combined filter for leucoreduction and prion removal, the same scheme was applied with RBC (suspended in Sag-M) issued from six animals intravenously infected with clarified brain homogenate from a vCJD-infected primate.


Results: In the BSE experiment, both primates injected with L-RBC before filtration developed an original neurological disease 30 and 31 months post inoculation and died 2 months later. This original neurodegenerative disease is described by E. Comoy et al. as an atypical form of prion disease. Conversely, all the three animals transfused with P-Capt[TRADEMARK] filtrated L-RBC still remained asymptomatic 54 months post transfusion. In the v-CJD experiment, first clinical signs evocative of the myelopathic syndrome were detected in both primates before filtration 20– 27 months post inoculation. One of them was subject to euthanasia 42 mpi, and pathological examination confirmed the occurrence of the myelopathic syndrome. The others animals are still asymptomatic.


Conclusions: The P-Capt was shown to be able to retain classical prion strains. Here in two independent experiments, we demonstrate that this filter is also able to retain atypical strains recently identified in primates after exposition to human blood products.




P-384


CONTAMINATED BLOOD PRODUCTS INDUCE AN ATYPICAL PRION DISEASE IN PRIMATES IN THE ABSENCE OF DETECTABLE ABNORMAL PRION PROTEIN


Comoy EEC1, Jaffre N1, Mikol J1, Durand V1, Luccantoni S1, Correia E1, Jas-Duval C2, Cheval J3, Eloit M4 and Deslys JP1


1Atomic Energy Commission, Fontenay-aux-Roses, France 2EFS, Lille, France 3Pathoquest, Paris, France 4Pasteur Institute, Paris, France


Background: Concerns about the blood-borne risk of prion infection have been confirmed by the occurrence in the UK of four transfusion-related infections of vCJD (variant Creutzfeldt-Jakob disease), and an apparently silent infection in an hemophiliac patient. Asymptomatic incubation periods in prion diseases can extend over decades in humans. Several parameters, including factors driving blood infectivity, remain poorly understand.


Aims: We used a validated non-human primate model of prion disease to evaluate the transfusional risk linked to v-CJD in human.


Methods: Cynomolgus macaques were inoculated with brain or blood specimens from vCJD infected humans and vCJD or BSE-infected monkeys. Neuropathological and biochemical findings were obtained using current methods used for human patients.


Results: Six out of 12 primates exposed to human or macaque blood-derived components exhibited after a long silent incubation period exceeding 5 years an original neurological disease (myelopathy) previously not described either in humans or primates, and which is devoid of the classical clinical and lesional features of prion disease (front leg paresis in the absence of central involvement, lesions concentrated in anterior horns of lower cervical cord, with no spongiosis or inflammation), while the nine brain-inoculated donor animals and one transfused animal exhibited the classical vCJD pattern, and the five other primates exposed to blood-derived components remain asymptomatic. No abnormal prion protein (PrPres) was detected by standard tests in use for human prion diagnosis. No alternative cause has been found in an exhaustive search for metabolic, endocrine, toxic, nutritional, vascular and infectious etiologies, including a search for pathogen genotypes (‘deep sequencing’). In secondary transmission experiments in primates, after shorter incubation periods (<2 a="" accumulation.="" and="" cord="" disease="" div="" induced="" inoculation="" intracerebral="" myelopathic="" of="" plasma="" prion="" prpres="" same="" spinal="" spongiosis="" syndrome="" the="" transfusion="" transmitted="" typical="" whereas="" with="" years="">

Conclusion: We describe a new neurological syndrome in monkeys exposed to various vCJD/BSE-infected blood components. Secondary transmission in primates confirm first the transmissibility of this myelopathy, and second its prion origin which could not be diagnosed as such in the first recipients. This myelopathy might be compared under some aspects to certain forms of human lower motor neuron diseases including neuromyelitis optica, the flail arm syndrome of ALS and the recently described FOSMN. Similar human infections, were they to occur, would not be identified as a prion disease by current diagnostic investigations.








Tuesday, May 21, 2013


IS ALZHEIMER’S DISEASE A PRION DISEASE? the possible secondary transmission by blood transfusion are posed








Sunday, May 19, 2013


CJD BLOOD SCREENING, DONORS, AND SILENT CARRIERS House of Commons Written Answers 16 May 2013






Monday, May 6, 2013


Warning of mad cow disease threat to blood transfusions








Tuesday, April 30, 2013


Mad cow infected blood 'to kill 1,000’








Friday, June 29, 2012


Highly Efficient Prion Transmission by Blood Transfusion








Tuesday, March 5, 2013


Use of Materials Derived From Cattle in Human Food and Cosmetics; Reopening of the Comment Period FDA-2004-N-0188-0051 (TSS SUBMISSION)


FDA believes current regulation protects the public from BSE but reopens comment period due to new studies








Tuesday, March 05, 2013


A closer look at prion strains Characterization and important implications Prion


7:2, 99–108; March/April 2013; © 2013 Landes Bioscience









Sunday, February 10, 2013


Creutzfeldt-Jakob disease (CJD) biannual update (February 2013) Infection report/CJD








Tuesday, May 7, 2013


Proteinopathies, a core concept for understanding and ultimately treating degenerative disorders?











TSS